J&J promis­es 20 new drugs to back phar­ma growth through end of decade, as John Reed shares his plans

John­son & John­son is lay­ing out its drug de­vel­op­ment am­bi­tions un­der its new R&D chief, pro­ject­ing that it will bring in bil­lions of dol­lars in added sales from new drugs in can­cer, im­munol­o­gy and oth­er ar­eas, as well as some high-risk bets in Alzheimer’s dis­ease.

The com­pa­ny shared the long-term pro­jec­tions as part of one of the busi­ness up­dates it holds every few years. J&J is fore­cast­ing that drug sales will grow 5% to 7% a year from 2025 to 2030, off a pro­ject­ed base of $57 bil­lion in 2025. And it’s promis­ing in­vestors 20 new drugs and 50 ex­pand­ed prod­ucts, in­clud­ing 10 with peak sales of $5 bil­lion or more.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER